Ursodeoxycholic Acid vs Metformin in Gestational Diabetes Mellitus
Status:
Not yet recruiting
Trial end date:
2022-06-30
Target enrollment:
Participant gender:
Summary
GUARD is a Clinical Trial that wants to explore the impact of UDCA compared to metformin in
the treatment of GDM. The trial wants to recruit 158 women who are overweight or obese who
have been diagnosed with GDM, and require pharmacological treatment. Glucose control is our
primary measure.
Each year in the UK approximately 35,000 women develop diabetes during pregnancy, a condition
called gestational diabetes mellitus (GDM), which increases the risk of adverse outcomes for
both mother and child. Metformin, although unlicensed for used in pregnancy, is the most
commonly used first line pharmacological treatment. However, there is increasing concern
about its widespread use during pregnancy, because of its limited efficacy and because of
potential safety concerns. Other common treatments have not been shown to be superior.
Therefore, there is an unmet need for additional therapies.
Ursodeoxycholic acid (UDCA) is commonly used in pregnancy for the treatment of intrahepatic
cholestasis of pregnancy. It is currently not an established/licensed treatment for GDM.
However data from observational studies of women with cholestasis in pregnancy has flagged
this to be a potential effective treatment to control blood glucose levels in GDM.
The investigators will ask women to attend three study visits, which will coincide with the
time of their antenatal appointments. The trial aims to collect a range of clinical and
research blood samples, to measure quality of life and treatment satisfaction through two
questionnaires, and will will ask women to wear a continuous glucose monitor for three 10 day
periods.
There will be a number of optional assessments that participants will be offered. The primary
outcome will be the fasting blood glucose concentration at 36 weeks of gestation.
The investigators intend to carry out this study at 3 sites in the United Kingdom (Guy's and
St Thomas, Imperial College and Nottingham), and it has been funded by a J.P Moulton
Foundation grant.